Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort

Launched by THOMAS SCHERER · Jul 15, 2024

Keywords

ClinConnect Summary

The MetAGE Deep Phenotyping Cohort trial is studying how obesity and aging affect our health. Researchers want to find certain markers in the blood that can indicate how aging is related to conditions like obesity, metabolic syndrome, and other age-related diseases. By understanding this relationship, they hope to develop better treatments and lifestyle changes in the future that can help people live healthier lives as they age.

To be eligible for this study, participants need to fall into specific age and weight categories. They are looking for young adults aged 18-35 who are either lean or overweight, older adults aged 60 and above with different weight classifications, and even those who are 90 years or older. Participants can expect to undergo tests and provide blood samples, but they need to meet certain health criteria to ensure their safety during the study. It’s important to note that this trial is not yet recruiting participants, so if you or someone you know might be interested, keep an eye out for updates!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Group 1 - Lean, young adults (n = 150)
• • Age 18 - 35 years
• • Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months)
• • Group 2 - Overweight, young adults (n = 150)
• • Age 18 - 35 years
• • BMI ≥ 28kg/m2 (≥ 12 months)
• • Group 3 - Lean, older adults (n = 150)
• • Age ≥ 60 years
• • BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years)
• • Group 4 - Overweight, older adults (n = 150)
• • Age ≥ 60 years
• • BMI ≥ 28 kg/m2 (≥ 3 years)
• • Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II).
• • Subgroup B (n=75): without pre-existent cardiovascular disease
• • Group 5 - Nonagenerians Age ≥ 90 (n = 50)
• • Age ≥ 90 years
• • BMI ≥ 18.5 kg/m2 (≥ 3 years)
• Exclusion Criteria:
• • Group 1 - Lean, young adults (n = 150)
• • Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
• • Special diets (i.e. ketogenic diet and time-restricted eating)
• • Clinically significant metabolic or endocrine disorders
• • Claustrophobia
• • drug abuse, alcohol \> 15 drinks/week
• • Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
• • Metal implants that prohibit 3T MRI
• • Pregnancy or breastfeeding
• • Group 2 - Overweight, young adults (n = 150)
• • Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
• • Special diets (i.e. ketogenic diet and time-restricted eating)
• • Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion)
• • Clinically significant metabolic or endocrine disorders
• • Claustrophobia
• • drug abuse, alcohol \> 15 drinks/week
• • Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
• • Metal implants that prohibit 3T MRI
• • Pregnancy or breastfeeding
• • Group 3 - Lean, older adults (n = 150)
• • Highly physical active (i.e. \> 5 times sporting activity / week with moderate to high intensity \[heart rate 140 - 200bpm\])
• • Special diets (i.e. ketogenic diet and time-restricted eating)
• • Diabetes, overt hypo/hyperthyroidism
• • Claustrophobia
• • drug abuse, alcohol \> 15 drinks/week
• • Metal implants that prohibit 3T MRI
• • Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) \< 35% or NYHA Class III-IV)
• • No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
• • Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
• • Group 4 - Overweight, older adults (n = 150)
• • Special diets (i.e. ketogenic diet and time-restricted eating)
• • Diabetes, overt hypo/hyperthyroidism
• • Active anti-obesity treatment (e.g. GLP-1 analogues, polyagonists, naltrexone and bupropion)
• • Claustrophobia
• • drug abuse, alcohol \> 15 drinks/week
• • Metal implants that prohibit 3T MRI
• • No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
• • Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
• • Group 5 - "healthy" Nonagenerians Age ≥ 90 (n = 50)
• • Claustrophobia
• • Clinically significant cognitive impairment compromising study adherence
• • Metal implants that prohibit 3T MRI
• • Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.